MYX 0.46% $4.38 mayne pharma group limited

BOOK value $7.60 per share, page-19

  1. 947 Posts.
    lightbulb Created with Sketch. 66
    THIS CAN JUMP AT ANY TIME , ONCE THEY REPORT BACK EBITDA +VE , WHICH THEY ALREADY DID 2HFY2023 , 6 MONTH ONCE THEY REPORT ON 1HFY2024 , EVERYONE WILL REGRET SELLINING AND THEY CANT EVEN BUY BACK . COMPARING THSI TO OTHER ASX ;LISTED COMPANIES WHO HAVE EVEN 3 TIMES THE MARKET CAP AND COMPANIES THAT DOESN'T EVEN HAVE ANY REVENUE , MAYNE WOULD STAND , ALL WHAT THEY NEED IS COST REDUCTION WHICH IS ACHIEVABLE , ONCE THE RESTRUCTURE IMPACT IS FELT . THIS WILL GO BACK TO WHERE IT WAS 2016 . BEST STRATEGY . REMEBER THEY NOW MAKING MONEY ON TXMD PRODUCTS WITH HALF THE OPEX AND SELLING NEXTSTELLIS WITH NO COST AMONGST THOSE PRODUCTS , 70 M SAVINGS , AND THEY WORKING ON IMPROVING THE NET SELLING PRICE THROUGH DISINTERMEDIATION .
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.